Kenvue Inc. (NYSE:KVUE - Get Free Report) has earned an average rating of "Hold" from the twelve brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $22.64.
A number of equities research analysts recently issued reports on KVUE shares. Jefferies Financial Group started coverage on shares of Kenvue in a research report on Tuesday, September 24th. They set a "buy" rating and a $27.00 target price for the company. JPMorgan Chase & Co. increased their price objective on shares of Kenvue from $24.00 to $25.00 and gave the stock an "overweight" rating in a report on Friday, October 11th. Royal Bank of Canada lowered shares of Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 price objective on the stock. in a report on Tuesday, September 24th. UBS Group increased their price objective on shares of Kenvue from $20.00 to $22.00 and gave the stock a "neutral" rating in a report on Wednesday, August 7th. Finally, Bank of America increased their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a report on Tuesday, October 22nd.
Get Our Latest Stock Analysis on KVUE
Shares of Kenvue stock opened at $23.04 on Tuesday. The stock has a market capitalization of $44.13 billion, a P/E ratio of 39.72, a price-to-earnings-growth ratio of 3.00 and a beta of 1.35. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. The company has a 50-day simple moving average of $22.55 and a 200 day simple moving average of $20.45. Kenvue has a 12-month low of $17.67 and a 12-month high of $23.55.
Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.28 by $0.04. The business had revenue of $4 billion during the quarter, compared to analysts' expectations of $3.93 billion. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The firm's revenue for the quarter was down .3% on a year-over-year basis. During the same quarter last year, the company posted $0.32 EPS. Research analysts expect that Kenvue will post 1.08 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be paid a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.56%. The ex-dividend date of this dividend is Wednesday, November 13th. Kenvue's dividend payout ratio (DPR) is presently 141.38%.
Hedge funds have recently modified their holdings of the business. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Kenvue in the 1st quarter valued at about $1,050,000. Lorne Steinberg Wealth Management Inc. raised its holdings in shares of Kenvue by 59.0% in the second quarter. Lorne Steinberg Wealth Management Inc. now owns 154,690 shares of the company's stock valued at $2,812,000 after purchasing an additional 57,375 shares during the last quarter. Kennon Green & Company LLC raised its holdings in shares of Kenvue by 140.7% in the second quarter. Kennon Green & Company LLC now owns 159,106 shares of the company's stock valued at $2,893,000 after purchasing an additional 93,008 shares during the last quarter. Czech National Bank raised its holdings in shares of Kenvue by 20.3% in the second quarter. Czech National Bank now owns 364,886 shares of the company's stock valued at $6,634,000 after purchasing an additional 61,635 shares during the last quarter. Finally, Crestwood Advisors Group LLC raised its holdings in shares of Kenvue by 14.8% in the second quarter. Crestwood Advisors Group LLC now owns 1,537,348 shares of the company's stock valued at $27,950,000 after purchasing an additional 198,607 shares during the last quarter. Institutional investors own 97.64% of the company's stock.
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.